Lake Street analyst Ben Haynor raised the firm's price target on InfuSystem to $17.50 from $15 and keeps a Buy rating on the shares. Although revenue fell below consensus in Q4, the firm was "pleased with the company's performance relative to our model" and trusts management to "make correct decisions leading to high ROIC," the analyst tells investors.
